版本:
中国

BRIEF-Sage Therapeutics announces the lancet publishes positive phase 2 brexanolone (sage-547) clinical data

June 12 Sage Therapeutics Inc:

* Sage Therapeutics announces the lancet publishes positive phase 2 brexanolone (sage-547) clinical data in severe postpartum depression

* Sage Therapeutics Inc says study showed significant mean reduction in 17-item hamilton rating scale for depression (ham-d) total score compared to placebo

* Sage Therapeutics-70 percent of subjects in study experienced remission of symptoms within 60 hours of treatment with brexanolone and maintained effect until 30-day follow-up

* Sage Therapeutics Inc - brexanolone was well-tolerated in this study with no observations of deaths, serious adverse events or discontinuations Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐